HARTE-HANKS INC (HHS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:HHS • US4161962026

2.93 USD
-0.08 (-2.66%)
Last: Feb 5, 2026, 08:00 PM
Fundamental Rating

3

Overall HHS gets a fundamental rating of 3 out of 10. We evaluated HHS against 91 industry peers in the Media industry. Both the profitability and the financial health of HHS get a neutral evaluation. Nothing too spectacular is happening here. HHS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • HHS had negative earnings in the past year.
  • HHS had a positive operating cash flow in the past year.
  • In multiple years HHS reported negative net income over the last 5 years.
  • In multiple years HHS reported negative operating cash flow during the last 5 years.
HHS Yearly Net Income VS EBIT VS OCF VS FCFHHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • HHS has a Return On Assets (-5.86%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of -27.25%, HHS is in line with its industry, outperforming 46.15% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 5.17%, HHS is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for HHS is above the industry average of 7.01%.
  • The last Return On Invested Capital (5.17%) for HHS is well below the 3 year average (11.53%), which needs to be investigated, but indicates that HHS had better years and this may not be a problem.
Industry RankSector Rank
ROA -5.86%
ROE -27.25%
ROIC 5.17%
ROA(3y)-0.4%
ROA(5y)1.73%
ROE(3y)14.69%
ROE(5y)N/A
ROIC(3y)11.53%
ROIC(5y)N/A
HHS Yearly ROA, ROE, ROICHHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

  • HHS has a Operating Margin (2.36%) which is in line with its industry peers.
  • In the last couple of years the Operating Margin of HHS has declined.
  • With a Gross Margin value of 18.47%, HHS is not doing good in the industry: 72.53% of the companies in the same industry are doing better.
  • HHS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 2.36%
PM (TTM) N/A
GM 18.47%
OM growth 3Y-15.64%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
HHS Yearly Profit, Operating, Gross MarginsHHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HHS is creating some value.
  • HHS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for HHS has been increased compared to 5 years ago.
  • HHS has a worse debt/assets ratio than last year.
HHS Yearly Shares OutstandingHHS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
HHS Yearly Total Debt VS Total AssetsHHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 14.55 indicates that HHS is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 14.55, HHS belongs to the top of the industry, outperforming 98.90% of the companies in the same industry.
  • HHS has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.03, HHS belongs to the top of the industry, outperforming 83.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 14.55
ROIC/WACC0.59
WACC8.84%
HHS Yearly LT Debt VS Equity VS FCFHHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

  • A Current Ratio of 1.48 indicates that HHS should not have too much problems paying its short term obligations.
  • HHS has a better Current ratio (1.48) than 60.44% of its industry peers.
  • A Quick Ratio of 1.48 indicates that HHS should not have too much problems paying its short term obligations.
  • HHS has a better Quick ratio (1.48) than 62.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
HHS Yearly Current Assets VS Current LiabilitesHHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

0

3. Growth

3.1 Past

  • HHS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.01%, which is quite impressive.
  • The Revenue for HHS has decreased by -11.07% in the past year. This is quite bad
  • Measured over the past years, HHS shows a decrease in Revenue. The Revenue has been decreasing by -3.17% on average per year.
EPS 1Y (TTM)82.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1650%
Revenue 1Y (TTM)-11.07%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-17.03%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HHS Yearly Revenue VS EstimatesHHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
HHS Yearly EPS VS EstimatesHHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HHS. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 2.71, the valuation of HHS can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of HHS indicates a rather cheap valuation: HHS is cheaper than 95.60% of the companies listed in the same industry.
  • HHS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.20.
Industry RankSector Rank
PE N/A
Fwd PE 2.71
HHS Price Earnings VS Forward Price EarningsHHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • 96.70% of the companies in the same industry are more expensive than HHS, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.92
HHS Per share dataHHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • HHS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • HHS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

HARTE-HANKS INC

NASDAQ:HHS (2/5/2026, 8:00:02 PM)

2.93

-0.08 (-2.66%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners31.83%
Inst Owner Change-2.5%
Ins Owners38.21%
Ins Owner Change0%
Market Cap21.71M
Revenue(TTM)166.84M
Net Income(TTM)-5.45M
Analysts80
Price TargetN/A
Short Float %0.91%
Short Ratio3.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.71
P/S 0.13
P/FCF N/A
P/OCF 13.83
P/B 1.09
P/tB 1.13
EV/EBITDA 1.92
EPS(TTM)-0.74
EYN/A
EPS(NY)1.08
Fwd EY36.88%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.21
OCFY7.23%
SpS22.52
BVpS2.7
TBVpS2.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.86%
ROE -27.25%
ROCE 6.55%
ROIC 5.17%
ROICexc 5.8%
ROICexgc 5.88%
OM 2.36%
PM (TTM) N/A
GM 18.47%
FCFM N/A
ROA(3y)-0.4%
ROA(5y)1.73%
ROE(3y)14.69%
ROE(5y)N/A
ROIC(3y)11.53%
ROIC(5y)N/A
ROICexc(3y)13.92%
ROICexc(5y)N/A
ROICexgc(3y)14.37%
ROICexgc(5y)N/A
ROCE(3y)14.59%
ROCE(5y)N/A
ROICexgc growth 3Y-18.32%
ROICexgc growth 5YN/A
ROICexc growth 3Y-18.73%
ROICexc growth 5YN/A
OM growth 3Y-15.64%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
F-Score6
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.06
Cap/Depr 42.33%
Cap/Sales 1.17%
Interest Coverage 250
Cash Conversion 18.34%
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z 14.55
F-Score6
WACC8.84%
ROIC/WACC0.59
Cap/Depr(3y)122.17%
Cap/Depr(5y)111.38%
Cap/Sales(3y)2.1%
Cap/Sales(5y)1.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1650%
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.07%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-17.03%
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.18%
EBIT growth 3Y-17.02%
EBIT growth 5YN/A
EBIT Next Year198.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-103.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.54%
OCF growth 3YN/A
OCF growth 5YN/A

HARTE-HANKS INC / HHS FAQ

What is the ChartMill fundamental rating of HARTE-HANKS INC (HHS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HHS.


What is the valuation status for HHS stock?

ChartMill assigns a valuation rating of 4 / 10 to HARTE-HANKS INC (HHS). This can be considered as Fairly Valued.


What is the profitability of HHS stock?

HARTE-HANKS INC (HHS) has a profitability rating of 4 / 10.


Can you provide the financial health for HHS stock?

The financial health rating of HARTE-HANKS INC (HHS) is 5 / 10.